3 days Ago By ABMN Staff
California Public Employees Retirement System lowered its holdings in shares of Amedisys, Inc. ( NASDAQ:AMED – Free Report ) by 29.8% during the fourth quarter, Holdings Channel reports.
The institutional investor owned 115,619 shares of the health services provider’s stock after selling 49,043 shares during the quarter. California Public Employees Retirement System’s holdings in Amedisys were worth $10,497,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Other institutional investors and hedge funds have also recently bought and sold shares of the company.
Vanguard Group Inc. boosted its position in shares of Amedisys by 0.3% during the 4th quarter.
Vanguard Group Inc. now owns 3,216,120 shares of the health services provider’s stock valued at $291,992,000 after acquiring an additional 10,817 shares in the last quarter. Norges Bank bought a new position in Amedisys during the fourth quarter worth about $83,061,000.
Alpine Associates Management Inc. boosted its holdings in Amedisys by 3.2% during the fourth quarter.
Alpine Associates Management Inc. now owns 888,120 shares of the health services provider’s stock valued at $80,632,000 after purchasing an additional 27,403 shares in the last quarter. Wealthfront Advisers LLC bought a new stake in shares of Amedisys in the 4th quarter valued at approximately $72,970,000.
Finally, Magnetar Financial LLC grew its stake in shares of Amedisys by 0.3% in the 4th quarter. Magnetar Financial LLC now owns 637,443 shares of the health services provider’s stock valued at $57,873,000 after purchasing an additional 1,835 shares during the period.
Institutional investors own 94.36% of the company’s stock. Analyst Ratings Changes Separately, Stephens reaffirmed an “equal weight” rating and issued a $101.
00 price target on shares of Amedisys in a research note on Tuesday, March 4th. Four equities research analysts have rated the stock with a hold rating and one has given a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $101.
00. Amedisys Trading Down 1.2 % Shares of AMED stock opened at $91.
89 on Monday. The company has a quick ratio of 1.19, a current ratio of 1.
19 and a debt-to-equity ratio of 0.05. The company has a market capitalization of $3.
01 billion, a P/E ratio of 36.46, a P/E/G ratio of 1.78 and a beta of 0.
76. Amedisys, Inc. has a 12-month low of $82.
15 and a 12-month high of $98.95. The firm has a 50-day moving average price of $92.
31 and a 200 day moving average price of $92.25. Amedisys ( NASDAQ:AMED – Get Free Report ) last announced its earnings results on Wednesday, February 26th.
The health services provider reported $0.96 EPS for the quarter, missing the consensus estimate of $1.05 by ($0.
09). The business had revenue of $598.05 million for the quarter, compared to the consensus estimate of $602.
38 million. Amedisys had a return on equity of 12.20% and a net margin of 3.
57%. Research analysts forecast that Amedisys, Inc. will post 4.
4 earnings per share for the current fiscal year. Amedisys Company Profile ( Free Report ) Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care.
The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients. Featured Articles Want to see what other hedge funds are holding AMED? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amedisys, Inc.
( NASDAQ:AMED – Free Report ). Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter .
.
